Self-reported cocaine use is not associated with elevations in high-sensitivity troponin I

Candice D. Jordan, Frederick Korley, Andrew Stolbach

Research output: Contribution to journalArticle

Abstract

Objective: High-sensitivity troponin (hsTn) assays detect 10 times lower concentrations of cardiac troponin than conventional assays. We examined the effects of self-reported cocaine use to determine whether those with acute cocaine use being evaluated for ACS are more likely to have elevated hsTnI than those nonusers being evaluated for ACS. Methods: We conducted a sub-analysis of a prospective cohort of ED patients evaluated for acute coronary syndrome. Recent cocaine use was determined by structured patient interviews. High-sensitivity troponin (Abbott) and conventional troponin I (Abbott, cTnI) were measured on samples drawn at presentation. Urine toxicology screen for cocaine metabolite was obtained at the discretion of treating clinicians. Results: Of 1862 patients enrolled, 444 reported prior cocaine use and 99 reported cocaine use within the preceding month. Median hsTn in patients with last cocaine use within 24 h, 2–7 days, 1 week–1 month, >1 month, and no prior cocaine use were: 9 (IQR: 3–17) ng/L, 6 (IQR: 3–24.3) ng/L, 6 (IQR: 3–89.5) ng/L, 3 (IQR: 3–18.5) ng/L and 3 (IQR: 3–17) ng/L, respectively. Urine toxicology assays (UTox) for cocaine were performed in 640 (34.4%) patients. The median hsTn for those who were UTox+, UTox − and those without a UTox were: 9 ng/L (IQR: 3–48.5), 9 ng/L (IQR: 3–40) and 3 ng/L (IQR: 3–12), respectively. There were no differences in the prevalence of new troponin elevations (hsTn >99th percentile but cTnI <99th percentile) in those with recent cocaine use compared to those without recent cocaine use. Conclusions: In this first investigation of hsTn in patients with self-reported recent cocaine use, we have determined that hsTn does not lead to an increase in the prevalence of troponin elevation in cocaine users.

Original languageEnglish (US)
Pages (from-to)1-6
Number of pages6
JournalClinical Toxicology
DOIs
StateAccepted/In press - Feb 8 2017

Fingerprint

Troponin I
Cocaine
Troponin
Assays
Toxicology
Urine
Acute Coronary Syndrome
Metabolites

Keywords

  • cocaine cardiotoxicty
  • cocaine MI
  • Cocaine toxicity

ASJC Scopus subject areas

  • Toxicology

Cite this

Self-reported cocaine use is not associated with elevations in high-sensitivity troponin I. / Jordan, Candice D.; Korley, Frederick; Stolbach, Andrew.

In: Clinical Toxicology, 08.02.2017, p. 1-6.

Research output: Contribution to journalArticle

@article{3ab9b680dac74018ad40d5513dfc5170,
title = "Self-reported cocaine use is not associated with elevations in high-sensitivity troponin I",
abstract = "Objective: High-sensitivity troponin (hsTn) assays detect 10 times lower concentrations of cardiac troponin than conventional assays. We examined the effects of self-reported cocaine use to determine whether those with acute cocaine use being evaluated for ACS are more likely to have elevated hsTnI than those nonusers being evaluated for ACS. Methods: We conducted a sub-analysis of a prospective cohort of ED patients evaluated for acute coronary syndrome. Recent cocaine use was determined by structured patient interviews. High-sensitivity troponin (Abbott) and conventional troponin I (Abbott, cTnI) were measured on samples drawn at presentation. Urine toxicology screen for cocaine metabolite was obtained at the discretion of treating clinicians. Results: Of 1862 patients enrolled, 444 reported prior cocaine use and 99 reported cocaine use within the preceding month. Median hsTn in patients with last cocaine use within 24 h, 2–7 days, 1 week–1 month, >1 month, and no prior cocaine use were: 9 (IQR: 3–17) ng/L, 6 (IQR: 3–24.3) ng/L, 6 (IQR: 3–89.5) ng/L, 3 (IQR: 3–18.5) ng/L and 3 (IQR: 3–17) ng/L, respectively. Urine toxicology assays (UTox) for cocaine were performed in 640 (34.4{\%}) patients. The median hsTn for those who were UTox+, UTox − and those without a UTox were: 9 ng/L (IQR: 3–48.5), 9 ng/L (IQR: 3–40) and 3 ng/L (IQR: 3–12), respectively. There were no differences in the prevalence of new troponin elevations (hsTn >99th percentile but cTnI <99th percentile) in those with recent cocaine use compared to those without recent cocaine use. Conclusions: In this first investigation of hsTn in patients with self-reported recent cocaine use, we have determined that hsTn does not lead to an increase in the prevalence of troponin elevation in cocaine users.",
keywords = "cocaine cardiotoxicty, cocaine MI, Cocaine toxicity",
author = "Jordan, {Candice D.} and Frederick Korley and Andrew Stolbach",
year = "2017",
month = "2",
day = "8",
doi = "10.1080/15563650.2017.1285404",
language = "English (US)",
pages = "1--6",
journal = "Clinical Toxicology",
issn = "1556-3650",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Self-reported cocaine use is not associated with elevations in high-sensitivity troponin I

AU - Jordan, Candice D.

AU - Korley, Frederick

AU - Stolbach, Andrew

PY - 2017/2/8

Y1 - 2017/2/8

N2 - Objective: High-sensitivity troponin (hsTn) assays detect 10 times lower concentrations of cardiac troponin than conventional assays. We examined the effects of self-reported cocaine use to determine whether those with acute cocaine use being evaluated for ACS are more likely to have elevated hsTnI than those nonusers being evaluated for ACS. Methods: We conducted a sub-analysis of a prospective cohort of ED patients evaluated for acute coronary syndrome. Recent cocaine use was determined by structured patient interviews. High-sensitivity troponin (Abbott) and conventional troponin I (Abbott, cTnI) were measured on samples drawn at presentation. Urine toxicology screen for cocaine metabolite was obtained at the discretion of treating clinicians. Results: Of 1862 patients enrolled, 444 reported prior cocaine use and 99 reported cocaine use within the preceding month. Median hsTn in patients with last cocaine use within 24 h, 2–7 days, 1 week–1 month, >1 month, and no prior cocaine use were: 9 (IQR: 3–17) ng/L, 6 (IQR: 3–24.3) ng/L, 6 (IQR: 3–89.5) ng/L, 3 (IQR: 3–18.5) ng/L and 3 (IQR: 3–17) ng/L, respectively. Urine toxicology assays (UTox) for cocaine were performed in 640 (34.4%) patients. The median hsTn for those who were UTox+, UTox − and those without a UTox were: 9 ng/L (IQR: 3–48.5), 9 ng/L (IQR: 3–40) and 3 ng/L (IQR: 3–12), respectively. There were no differences in the prevalence of new troponin elevations (hsTn >99th percentile but cTnI <99th percentile) in those with recent cocaine use compared to those without recent cocaine use. Conclusions: In this first investigation of hsTn in patients with self-reported recent cocaine use, we have determined that hsTn does not lead to an increase in the prevalence of troponin elevation in cocaine users.

AB - Objective: High-sensitivity troponin (hsTn) assays detect 10 times lower concentrations of cardiac troponin than conventional assays. We examined the effects of self-reported cocaine use to determine whether those with acute cocaine use being evaluated for ACS are more likely to have elevated hsTnI than those nonusers being evaluated for ACS. Methods: We conducted a sub-analysis of a prospective cohort of ED patients evaluated for acute coronary syndrome. Recent cocaine use was determined by structured patient interviews. High-sensitivity troponin (Abbott) and conventional troponin I (Abbott, cTnI) were measured on samples drawn at presentation. Urine toxicology screen for cocaine metabolite was obtained at the discretion of treating clinicians. Results: Of 1862 patients enrolled, 444 reported prior cocaine use and 99 reported cocaine use within the preceding month. Median hsTn in patients with last cocaine use within 24 h, 2–7 days, 1 week–1 month, >1 month, and no prior cocaine use were: 9 (IQR: 3–17) ng/L, 6 (IQR: 3–24.3) ng/L, 6 (IQR: 3–89.5) ng/L, 3 (IQR: 3–18.5) ng/L and 3 (IQR: 3–17) ng/L, respectively. Urine toxicology assays (UTox) for cocaine were performed in 640 (34.4%) patients. The median hsTn for those who were UTox+, UTox − and those without a UTox were: 9 ng/L (IQR: 3–48.5), 9 ng/L (IQR: 3–40) and 3 ng/L (IQR: 3–12), respectively. There were no differences in the prevalence of new troponin elevations (hsTn >99th percentile but cTnI <99th percentile) in those with recent cocaine use compared to those without recent cocaine use. Conclusions: In this first investigation of hsTn in patients with self-reported recent cocaine use, we have determined that hsTn does not lead to an increase in the prevalence of troponin elevation in cocaine users.

KW - cocaine cardiotoxicty

KW - cocaine MI

KW - Cocaine toxicity

UR - http://www.scopus.com/inward/record.url?scp=85011878231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011878231&partnerID=8YFLogxK

U2 - 10.1080/15563650.2017.1285404

DO - 10.1080/15563650.2017.1285404

M3 - Article

SP - 1

EP - 6

JO - Clinical Toxicology

JF - Clinical Toxicology

SN - 1556-3650

ER -